Anti-IgE Treatment for Disorders Other Than Asthma
نویسندگان
چکیده
منابع مشابه
Anti-IgE Treatment for Disorders Other Than Asthma
Immunoglobulin E (IgE) plays a key role in the pathogenesis of many allergic diseases. Thus, IgE-mediated immunologic pathways are an attractive target for intervention in allergic diseases. Omalizumab is a recombinant humanized monoclonal antibody that binds IgE and has been used treat allergic asthma for over a decade. Currently, omalizumab is approved for the treatment of both allergic asthm...
متن کاملAnti-IgE: beyond asthma
Omalizumab (anti-IgE ab) is a recombinant humanized monoclonal antibody (rhuMAb-E25) developed by immunizing mice with human IgE. Then, a monoclonal antibody was selected that recognizes IgE at the same site as the highaffinity receptor for IgE (FcεRI). Omalizumab is the only Mab to date that has been found to be effective and approved by both the FDA and European Medicines Agency (EMA) for the...
متن کاملAnti-IgE antibody for the treatment of allergic asthma.
Xolair is a monoclonal antibody that binds the Cε3 domain of IgEs, inducing a conformational change of the immunoglobulin, a concealment of FcεRI and FcεRII receptors binding sites, thus precluding binding by IgEs and therefore stopping the release of inflammation mediators. Xolair is indicated as add-on therapy to improve/control asthma in adult and adolescent patients (12 years of age and abo...
متن کاملAnti- IgE treatment in asthma: is atopy essential?
Methods Case 1, a fifty one-year old woman who has been treated for 11 years diagnosis of asthma, went to emergency service four times last year in spite of taking high dose inhaler corticosteroid. In her physical examination widespread rhonchi was oscultated. FEV1: %76, total IgE: 897 IU/mL inhalant skin prick tests and mites spesific IgE were negative. Visual Analog Score(VAS) was 2, asthma s...
متن کاملAnti-IgE monoclonal antibody for the treatment of the asthma and other manifestations related to allergic diseases.
OBJECTIVES To report on the pharmacology, efficacy and safety of omalizumab, a new option for the treatment of asthma and allergic diseases and the first monoclonal anti-IgE antibody approved for clinical use. SOURCES MEDLINE, a non-systematic search including reviews and original papers, chosen according to their relevance in the authors' opinion. SUMMARY OF THE FINDINGS The paper emphasiz...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Medicine
سال: 2017
ISSN: 2296-858X
DOI: 10.3389/fmed.2017.00152